Business Wire

VA-REGULA

16.1.2024 08:01:33 CET | Business Wire | Press release

Share
Regula Survey Reveals 80% of Decision Makers Link Digital Nomad Movement to Increased Identity Fraud

According to the survey’s results, the number of foreign document verification cases in all parts of the world has grown by an average of 21% since the summer of 2021. It’s even higher in the US and UAE: these countries are experiencing a 25% increase. As for industries, Insurance appears to be dealing with the majority of foreign IDs (+27% compared to summer 2021), followed by Financial and Banking Services (+25%).

The rise in foreign clients has led to a spike in identity fraud. Identity verification (IDV) of digital nomads can be a tricky task for many businesses as their established processes are not designed for such a large variety of foreign IDs, and thus require revamping. This difficulty potentially results in an elevated risk of organizations facing more identity fraud. Indeed, Regula’s survey confirms these sentiments among business decision makers, with 40% of them highlighting the increase in fraud as a primary challenge when it comes to identity verification for digital nomads. The UAE and Mexico are even more agitated, as 51% and 49% of decision makers in those countries feel the risk of falling victim to fraud.

Furthermore, 80% of decision makers participating in Regula’s survey directly associate the digital nomad movement with identity fraud, saying that it is increasing the number of forged or counterfeited documents organizations find during verification. The average growth in identity document fraud is stated to be 14%; however, in the Insurance industry it is 22%, and in the Financial and Banking Services it is nearly 19%.

New solution. This situation is forcing businesses to introduce new methods and technologies for identity verification. As the survey shows, 57% of organizations have implemented biometric authentication to detect and prevent fraud during the digital onboarding process. To combat document forgery, 53% of respondents say they have decided to verify only electronic documents—i.e., ones that contain an RFID chip, a reliable security feature that makes counterfeiting almost impossible. The most vulnerable industries, Financial Services and Insurance, are even more inclined to switch to this option: 61% of decision makers from these sectors confirmed they are already accepting only e-docs.

The option to grant access to products and services only to digital nomads who have electronic documents seems to be an effective measure. It can help organizations cope with the growing number of various IDs by limiting their possible variety. It also facilitates document verification, since e-docs are currently considered to be the most secure. However, to be able to combat document fraud, it’s not enough to rely only on document security features. While it’s nearly impossible for fraudsters to counterfeit a microchip in an electronic passport, they can still manipulate its data or intercept verification results on a smartphone. That is why organizations need a “zero-trust-to-mobile” approach and a reliable NFC verification technology to confirm the authenticity of both the chip and its data. A good example is Regula Document Reader SDK: it enables complete server-side verification of e-documents to ensure the chip's authenticity and data integrity.

“Identity fraud is flourishing, and overall digitalization, along with mass people movement and relocation are creating new pitfalls for businesses, which are trying to keep pace. In this changing world, organizations inevitably need to start adopting new technologies to enable robust and reliable verification, especially for remote processes. They will also be interested in the possibilities to scale and adapt their IDV processes to new scenarios and requirements. Leading vendors like Regula are responding to this shift as well, by introducing new technologies and capabilities for any use case in any industry,” says Henry Patishman, Executive Vice President, Identity Verification Solutions at Regula.

To learn more about the identity fraud associated with the digital nomad movement, read the full report.

*The research was initiated by Regula and conducted by Sapio Research in September 2023 using an online survey of digital nomads and Fraud Prevention decision makers across the Software/Tech, Financial and Banking Services, Technology, Telecoms, Travel and Hospitality sectors, and others. The respondent geography included the US, UK, Germany, Spain, UAE, and Mexico.

About Regula

With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.

Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.

Learn more at regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240115684173/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye